Using pegylated interferon alfa-2b and ribavirin to treat chronic hepatitis patients infected with hepatitis c virus genotype 1: are nonresponders and relapsers different populations?

Using pegylated interferon alfa-2b and ribavirin to treat chronic hepatitis patients infected with hepatitis c virus genotype 1: are nonresponders and relapsers different populations?

The combination of pegylated interferon (PEG-INF) and ribavirin is currently the best treatment for chronic hepatitis C, providing a sustained virological response (SVR) in 54%-63% of patients. In patients infected with hepatitis C virus (HCV) genotype 1, the SVR rate is 42%-52%. To evaluate the tre...

Full description

Bibliographic Details
Main Authors:	Giovanni Faria Silva, Rodrigo José Polônio, Maria Inês Moura Campos Pardini, Silvia Maria Corvino, Rita Maria Saccomano Henriques, Mari Nilce Peres, Liciana Vaz Arruda Silveira, Kunie Iabuki Rabello Coelho
Format:	Article
Language:	English
Published:	Elsevier
Series:	Brazilian Journal of Infectious Diseases
Subjects:	Hepatitis C pegylated interferon alfa 2b genotype 1 relapsers
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702007000600006&lng=en&tlng=en

Similar Items

Pityriasis Rosea Associated with Pegylated Interferon Alfa and Ribavirin Treatment in a Patient with Chronic Hepatitis C
by: Rahmet Güner, et al.
Published: (2013-06-01)

Response factors to pegylated interferon-alfa/ribavirin treatment in chronic hepatitis C patients genotype 1b
by: Jovanović-Ćupić Snežana, et al.
Published: (2014-01-01)

Psoriasis induced by Interferon alfa-2a and ribavirin in a patient followed for hepatitis C
by: N. Amraoui, et al.
Published: (2015-07-01)

Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers
by: Marisa Boff Costa, et al.
Published: (2018-01-01)

Autoimmune thyroid diseases in patients with chronic hepatitis C treated by pegylated interferon-alpha and ribavirin: A prospective study
by: Ružić Maja, et al.
Published: (2017-01-01)

EFFICACY AND SAFETY OF THE COMBINATION OF RIBAVIRIN AND PEGYLATED INTERFERON ALFA-2A IN PATIENTS WITH CHRONIC HEPATITIS C: THE RESULTS OF TWO MULTICENTER, PROSPECTIVE, OPEN, NON-COMPARATIVE CLINICAL TRIALS
by: K. V. Zhdanov, et al.
Published: (2018-01-01)

Early virologic response to сеpeginterferon alfa-2b in combination with ribavirin in treatment of patients with chronic hepatitis C
by: O. O. Znoyko, et al.
Published: (2014-09-01)

Efficacy of combined antiviral therapy with pegylated interferon α-2a and ribavirin for chronic hepatitis C infection in intravenous drug users
by: Ružić Maja, et al.
Published: (2010-01-01)

Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon – Ribavirin in daily practice
by: Ezequiel Ridruejo, MD., et al.
Published: (2010-01-01)

Characteristics of hepatitis C treatment with pegylated interferons and ribavirin
by: Ricardo Jiménez-Méndez, et al.
Published: (2010-01-01)

Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy
by: E. Parise, et al.

Pegylated Interferon (Alone or With Ribavirin) for Chronic Hepatitis C in Haemodialysis Population
by: Mario Espinosa, et al.
Published: (2015-05-01)

The sustained virologic response of nonresponder hepatitis C virus patients with retreatment
by: Sila Cetin Akhan, et al.
Published: (2011-01-01)

Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting
by: Sergio Sabbatani, et al.

Effect of Pegylated Interferon on Non-Responders and Relapsers with Interferon
by: Hisham O. Akbar, et al.
Published: (2002-04-01)

Sustained virological response to treatment of chronic hepatitis C with peginterferon alfa and ribavirin
by: Junior André da Rosa, et al.
Published: (2012-06-01)

Cutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C
by: Elson Vidal Martins Jr., et al.
Published: (2009-11-01)

Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment
by: Ming-Hui Li, et al.
Published: (2017-01-01)

HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b
by: Hui Ma, et al.
Published: (2016-01-01)

Successful Antiviral and Antituberculosis Treatment With Pegylated Interferon-alfa and Ribavirin in a Chronic Hepatitis C Patient With Pulmonary Tuberculosis
by: Ming-Chao Tsai, et al.
Published: (2009-09-01)

DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN
by: Izabella Liguori Corsino VABO, et al.

Acute hepatitis C treatment
by: Paulo Roberto Lerias de Almeida
Published: (2010-01-01)

Side Effects of Therapy for Chronic Hepatitis C: High Incidence of Dermal and Mucosal Adverse Events
by: Hüseyin Şener BARUT, et al.
Published: (2010-03-01)

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
by: Zhen Yuan, et al.
Published: (2021-01-01)

Evaluation of the Results of Patients Treated By Pegylated Interferon Alpha Therapy
by: Çiğdem PAPİLA, et al.
Published: (2015-09-01)

Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan
by: Jung-An Lin, et al.
Published: (2014-10-01)

Replication of hepatitis C virus in peripheral blood mononuclear cells in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin
by: Malgorzata Inglot, et al.
Published: (2013-03-01)

Polyethylene Glycol Exposure with Antihemophilic Factor (Recombinant), PEGylated (rurioctocog alfa pegol) and Other Therapies Indicated for the Pediatric Population: History and Safety
by: Reinhard Stidl, et al.
Published: (2018-07-01)

The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients
by: Nishikawa Hiroki, et al.
Published: (2012-03-01)

The interleukin 28B gene polymorphism, rs8099917, in patients with chronic hepatitis C and response to the treatment with pegylated interferon and ribavirin
by: Hamid Kalantari, et al.
Published: (2019-01-01)

Importance of adherence for efficacy of hepatitis C combined therapy
by: Nožić Darko, et al.
Published: (2013-01-01)

Five-year follow-up of patients with chronic C hepatitis and sustained virological response Seguimiento a 5 años de pacientes con hepatitis crónica C y respuesta viral sostenida
by: I. Puig-del-Castillo, et al.
Published: (2011-02-01)

Pulmonary hazards of chronic hepatitis C virus infection treatment with Pegylated interferon and ribavirin vs. untreated patients
by: Sanaa Elhelaly, et al.
Published: (2013-04-01)

Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study
by: Anuja Pandit, et al.
Published: (2021-04-01)

Autoantibodies profile in patients with chronic hepatitis C and the influence of Interferon-alfa plus Ribavirin
by: Janaina LeitÃo Vilar
Published: (2006)

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
by: Janine Hartl, et al.
Published: (2012-07-01)

Autoimmune manifestation of hepatitis C virus infection as a risk for late virological relapse after pegylated interferon and ribavirin therapy
by: Ružić Maja, et al.
Published: (2018-01-01)

Antiviral/immunomodulatory combination therapy: Pegylated interferon alpha 2a and ribavirin in patients with chronic hepatitis C virus infection
by: Delić Dragan, et al.
Published: (2012-01-01)

Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT
by: Jaber Al-Ali, et al.
Published: (2012-03-01)

Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C
by: C Kondo, et al.
Published: (2016-01-01)